Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation

Incyte ($INCY) announced an update on their ongoing clinical study. Incyte Corporation has recently completed a clinical study titled An Open-Label...

Incyte’s Latest Study Completion: A Step Forward in Drug Interaction Insights

Incyte ( ($INCY) ) has provided an announcement. On December 10, 2025, Hervé Hoppenot announced his retirement from Incyte Corporation’s Board of D...

Incyte Board Member Hervé Hoppenot Retires

In a report released today, Kelly Shi from Jefferies maintained a Buy rating on Incyte, with a price target of $120.00. According to TipRanks, Shi ...

Jefferies Keeps Their Buy Rating on Incyte (INCY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY – Research Report), Fulcrum Therapeut...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Fulcrum Therapeutics (FULC) and Arcellx Inc (ACLX)

Evercore ISI analyst maintained a Hold rating on Incyte today and set a price target of $73.00. In addition to Evercore ISI, Incyte also received a...

Incyte (INCY) Gets a Hold from Evercore ISI

Guggenheim analyst Michael Schmidt reiterated a Buy rating on Incyte yesterday and set a price target of $125.00. According to TipRanks, Schmidt is...

Guggenheim Remains a Buy on Incyte (INCY)

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte, with a price target of $101.00. According to TipRanks, Frah...

TD Cowen Sticks to Its Buy Rating for Incyte (INCY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immatics (IMTX – Research Report), Incyte (INCY – Research Report...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Cogent Biosciences (COGT)

Barclays analyst Etzer Darout maintained a Buy rating on Incyte today and set a price target of $115.00. Darout covers the Healthcare sector, focus...

Incyte (INCY) Receives a Buy from Barclays

The SPDR S&P 500 ETF Trust ($SPY) gained 0.55% on Friday, primarily driven by a rally in chip stocks, optimism about potential future Federal Reser...

SPY ETF Daily Update, 11/28/2025

The Vanguard S&P 500 ETF ($VOO) rose 0.93% on Wednesday, supported by renewed optimism over possible Federal Reserve rate cuts and strength in tech...

Vanguard S&P 500 ETF (VOO) Daily Update, 11/27/2025

The Vanguard S&P 500 ETF ($VOO) rose 0.93% on Tuesday, supported by growing expectations of Federal Reserve rate cuts and upbeat earnings from reta...

Vanguard S&P 500 ETF (VOO) Daily Update, 11/26/2025

The SPDR S&P 500 ETF Trust ($SPY) rose 0.99% on Friday, as the New York Fed President John Williams’ speech revived hopes of an interest rate cut i...

SPY ETF Daily Update, 11/24/2025

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Incyte, with a price target of $115.00. According to TipRanks, Da...

Barclays Sticks to Their Buy Rating for Incyte (INCY)

The Vanguard S&P 500 ETF ($VOO) gained 0.36% on Wednesday, snapping a four-day slide. The ETF is also up 1.10% in pre-market trading today after Nv...

Vanguard S&P 500 ETF (VOO) Daily Update, 11/20/2025

Jefferies analyst Kelly Shi maintained a Buy rating on Incyte today and set a price target of $120.00. Shi covers the Healthcare sector, focusing o...

Jefferies Remains a Buy on Incyte (INCY)

The SPDR S&P 500 ETF Trust ($SPY) closed 0.02% lower on Friday. Volatility in the technology sector and concerns about a potential delay in Federal...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INCY	$95.41	-0.72%	2.26M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INCY	$95.41	-0.7%	2.26M
3
4
5
6

INCY

INCY

Get Incyte Corporation Data in Excel

Get Incyte Corporation Data in Excel